Jeena Sikho Lifecare will host a physical group meeting with investors and analysts on August 31, 2026. The company announced the engagement as part of the GIA Healthcare Day, aiming to discuss its business outlook with stakeholders.

The session is scheduled from 3:30 pm to 5:00 pm at the Jio World Convention Centre in Mumbai’s Bandra Kurla Complex. Management will lead the discussions, providing updates on the company’s operations and strategic direction.

Meeting Details

The interaction is structured as a physical group meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule remains indicative and may change due to unforeseen developments by the company or the organizer.

Participants interested in attending can register via the access link provided in the original intimation. The company confirmed that discussions will rely solely on publicly available documents.

Regulatory Disclosure

Jeena Sikho Lifecare stated that no unpublished price-sensitive information (UPSI) will be discussed during the interaction. This ensures compliance with market fairness norms and prevents selective disclosure of material data.

The intimation was issued by Manish Grover, Managing Director of Jeena Sikho Lifecare Limited, on August 25, 2026. The notice was simultaneously filed with the National Stock Exchange of India Limited and BSE Limited.

Jeena Sikho Lifecare Limited reported a 29% year-on-year increase in revenue from operations to ₹224.4 crore for the quarter ended June 30, 2026 (Q1 FY27), compared to ₹174.3 crore in the corresponding period of the previous fiscal year. The growth was primarily driven by strong performance in its private-pay Panchakarma hospitalisation segment and a rapid expansion in its digital medicine channel.

The company’s strategic shift towards private-pay patients is evident in the operational data. Private-pay inpatient department (IPD) admissions rose 33% to 11,500, contributing ₹84.8 crore to revenue, a 26% increase year-on-year. This robust volume growth helped offset a significant contraction in government-panel IPD revenue, which fell 67% to ₹5.2 crore from ₹15.5 crore in Q1 FY26. Consequently, the share of government-panel revenue in total revenue dropped from 8.9% to 2.3%.

Revenue Breakdown by Channel

Healthcare services revenue increased 13% to ₹106.0 crore. While private-pay IPD alone would have shown a 26% growth rate, the blended services growth was moderated by the decline in government-panel activity. On a fully blended basis including day-care but excluding diagnostics and consultation, total IPD volume grew 16.9% while total IPD revenue rose 8.8%.

What the Numbers Show

The divergence between headline revenue growth and services revenue growth highlights a deliberate mix shift. Private-pay IPD admissions grew 33%, yet blended healthcare services revenue expanded only 13%. This gap is explained by the collapse in government-panel revenue, which declined by ₹10.3 crore. Management has flagged government-panel schemes as carrying slower collections, implying weaker cash conversion. By reducing exposure to this segment, the company is trading top-line acceleration in the services vertical for improved earnings quality and cash flow predictability, consistent with its stated strategy of remaining predominantly private-pay.

Acharya Manish Grover, Managing Director and Chairman, noted that the quarter reflected continued scale-up across the integrated healthcare and medicines platform. He emphasized that the company remains focused on disciplined centre economics, patient outcomes, and sustainable profitable growth as the network expands.